tolebrutinib

News

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.

News

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data

News

Two of three trials fail, but Sanofi will still file MS drug

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of thr

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's tolebrutinib cuts MS progression by 31% in trial

Two of three trials fail, but Sanofi will still file MS drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks